Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective56
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting25
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation22
Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam17
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts16
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants16
It’s about time: The association between abacavir and cardiovascular disease15
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity13
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway9
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud8
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines7
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report7
Pharmacokinetic and mass balance characterization of [ 14 C] RAY1216, a SARS-CoV-2 M pro inhibitor7
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review6
A favipiravir-induced angioedema and urticaria in a COVID-19 patient6
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach6
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study5
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)5
The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis5
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine5
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database5
0.035015821456909